Mov Disord Vol 35, Suppl 1 Archives - Page 124 of 149 - MDS Abstracts

MDS Virtual Congress 2020
A novel POLG2 variant leads to disrupted mitochondrial integrity in a family with cerebellar ataxia and progressive ophthalmoplegia
K. Lohmann, M. Borsche, H. Baumann, S. Tunc, E. Knappe, S. Özcakir, J. Trinh, M. Dulovic-Mahlow, N. Brüggemann (Luebeck, Germany)
Objective: To investigate the molecular consequences of a variant of unknown significance (VUS) in POLG2. Background: Mitochondrial DNA (mtDNA) is replicated by DNA polymerase gamma,…
MDS Virtual Congress 2020
Huntington’s disease in Egypt; A big challenge for a mysterious disease
S. El-Jaafary, A. Sabbah, H. Amer (Cairo, Egypt)
Objective: To identify the challenges of managing Huntington’s disease in Egypt in order to overcome them. Background: Huntington’s disease (HD) is considered a rare disease…
MDS Virtual Congress 2020
Healthcare Utilization and Cost Burden at the End-of-Life Among Medicare Beneficiaries with Huntington’s Disease
S. Reddy, A. Exuzides, E. Chang, C. Paydar, G. Yohrling (Beverly Hills, CA, USA)
Objective: To examine healthcare utilization (HCU) and costs occurring at the end of life among deceased Medicare beneficiaries who were diagnosed with Huntington’s disease (HD).…
MDS Virtual Congress 2020
Myoclonic epilepsy with ragged-red fibers: the first described clinical case in Ukraine
Y. Trufanov, N. Svyrydova, A. Galusha, V. Sereda, V. Svistun, I. Zarashchak, A. Yanchak (Kyiv, Ukraine)
Objective: To provide a description of a case of myoclonic epilepsy with ragged-red fibers (MERRF) diagnosed in Kyiv, Ukraine. Background: MERRF is a rare mitochondrial…
MDS Virtual Congress 2020
Tau Neuropathology Associates with In Vivo Patterns of Neurodegeneration in Lewy Body Disorders
N. Spotorno, D. Coughlin, L. Shaw, A. Chen-Plotkin, D. Weintraub, E. Lee, J. Trojanowski, C. McMillan, D. Irwin, M. Grossman (Philadelphia, PA, USA)
Objective: Investigate the impact of Alzheimer’s disease (AD) co-pathology on an in vivo structural measure of neurodegeneration in Lewy Body disorders (LBD: Parkinson’s Disease and…
MDS Virtual Congress 2020
Hyperpolarization of the subthalamic nucleus alleviates hyperkinetic movement disorders
C.H Tai, S.H Tseng, T.R Wang, M.T Hsu, C-C. Kuo (Taipei, Taiwan)
Objective: We test the hypothesis of modulating subthalamic neuronal firing pattern via injection of hyperpolarizing current as an effective treatment for hyperkinetic movement disorders. Background:…
MDS Virtual Congress 2020
The clinical spectrum of movement disorders associated with neuronal antibodies
V. Karthikeayan, A. Randall, E. Jackson, S. Huda, M. Bonello (Liverpool, United Kingdom)
Objective: To describe the clinical and treatment characteristics of movement disorders associated with antibodies (Abs) against neuronal synaptic extracellular (NMDAR, LGI1, CASPR2, IgLON5, Glycine receptors…
MDS Virtual Congress 2020
Say “AH~”: Vocal Analysis in Parkinson’s Disease and Essential Tremor
J.E Park, S.W Oh, J.Y Shin, S.Y Lee, S.H Hong, N.H Ahn, H.J Kim, K.H Lee, J.E Bae, H.B Lee (Goyang, Republic of Korea)
Objective: We aimed to investigate useful vocal parameters in differentiating PD and ET, using a machine-learning algorithm. Background: Correlation between Parkinson's disease (PD) and essential tremor (ET)…
MDS Virtual Congress 2020
The Future of Hospitalization for People with Parkinson’s Disease
A. Wallis, D. Perret (Miami, FL, USA)
Objective: To share the discussion of the December 6, 2019 Parkinson’s Hospitalization Convening. Background: On December 6, 2019, The Parkinson’s Foundation (PF) assembled thought leaders…
MDS Virtual Congress 2020
Confrontation Naming Deficit in Lewy Body Dementia Patients with Alzheimer’s Disease Co-Pathology
E. Howard, D. Irwin, K. Rascovsky, N. Nevler, S. Shellikeri, D. Mechanic-Hamilton, T. Tropea, A. Chen-Plotkin, A. Siderowf, D. Weintraub, L. Shaw, J. Trojanowski, M. Grossman, K. Cousins (Philadelphia, PA, USA)
Objective: To test the association between confrontation naming performance and Alzheimer’s disease (AD) co-pathology as defined by cerebrospinal fluid (CSF) biomarkers in Lewy body dementia…